LDN for IBS and Gut Health: Pain, Motility, and Where GLP-1s Fit

Search for Low Dose Naltrexone and gut health, and the claims can escalate quickly. LDN is described as reducing abdominal pain, improving motility, calming inflammation, repairing the intestinal lining, treating SIBO, or “healing the gut.”

The direct IBS evidence is far less certain.

A small 2006 open-label pilot reported improvement during four weeks of treatment. But a larger randomized, double-blind, placebo-controlled Phase 3 trial in 609 women did not demonstrate meaningful benefit at three months, its primary endpoint. The manufacturer discontinued development of the investigational product.

That larger negative result is often missing from online summaries.

Direct answer: LDN is not FDA approved or established as a treatment for irritable bowel syndrome. A 42-person open-label pilot reported improvement, but a 609-woman randomized Phase 3 trial missed its primary endpoint. LDN has not been proven to normalize bowel motility, treat SIBO, repair “leaky gut,” or replace guideline-supported IBS care. Semaglutide and tirzepatide are also not established IBS treatments and may cause gastrointestinal effects that overlap with IBS symptoms.

Explore Patient-Specific Options With Scripx

Interested in a patient-specific LDN prescription? View Scripx Pharmacy's Low Dose Naltrexone information and ask a licensed prescriber whether an off-label evaluation is appropriate for a clearly defined symptom goal.

Evaluating GLP-1 therapy for a separate metabolic goal? Explore Scripx Pharmacy's medically supervised weight-management services.

Need help with a prescription or formulation question? Contact the Scripx Pharmacy team or learn about Scripx compounding services.

All prescription medications require evaluation by a licensed healthcare provider. LDN use for IBS is off label. Compounded medications are not FDA approved. New, severe, persistent, or changing gastrointestinal symptoms require appropriate medical evaluation.

Ready to Get Started?

Explore available treatment options and complete a secure health questionnaire for provider review.

View Products & Start Your Order →

Prescription medications require an individual medical evaluation and, when appropriate, a prescription from a licensed healthcare provider. Completing a questionnaire does not guarantee treatment or a prescription.

IBS Is a Disorder of Gut-Brain Interaction

Irritable bowel syndrome, or IBS, is a chronic disorder of gut-brain interaction characterized by recurrent abdominal pain associated with changes in bowel habits. Depending on the predominant stool pattern, it may be categorized as IBS with constipation, IBS-C, IBS with diarrhea, IBS-D, mixed IBS, IBS-M, or unclassified IBS.

IBS can involve pain, cramping, bloating, urgency, constipation, diarrhea, mucus, and a sense of incomplete evacuation. Symptoms may vary over time and can be influenced by meals, stress, sleep, menstrual cycles, infections, medications, and other factors.

“Disorder of gut-brain interaction” does not mean symptoms are imaginary. It describes altered communication among the gastrointestinal tract, nervous system, immune signaling, motility, sensation, and behavioral or environmental factors. Pain can be severe even when standard imaging or endoscopy does not show structural damage.

The American College of Gastroenterology recommends a positive diagnostic strategy rather than treating IBS only as a diagnosis of exclusion. Depending on the symptom pattern, evaluation may include celiac testing and fecal calprotectin to help distinguish IBS-D from celiac disease or inflammatory bowel disease. Guideline-supported options vary by subtype and may include a limited low-FODMAP trial, specific constipation or diarrhea medications, and gut-directed psychotherapy. Review the ACG IBS guideline.

LDN is not included as a recommended IBS treatment in that guideline.

Symptoms That Should Not Automatically Be Labeled IBS

IBS is common, but not every episode of abdominal pain, constipation, diarrhea, or bloating is IBS. A clinician may need to consider infection, celiac disease, inflammatory bowel disease, microscopic colitis, medication effects, pelvic-floor dysfunction, thyroid disease, pancreatic or gallbladder disease, colorectal cancer, or another diagnosis.

Prompt medical evaluation is especially important for symptoms such as:

• Blood in the stool or black stool

• Unexplained weight loss

• Iron-deficiency anemia

• Persistent fever

• Repeated vomiting or inability to keep fluids down

• Severe or progressively worsening pain

• Symptoms that repeatedly wake a person from sleep

• A new bowel-pattern change later in life

• A family history of colorectal cancer, inflammatory bowel disease, or celiac disease

• Signs of dehydration, obstruction, or severe constipation

An off-label medication trial should not delay an appropriate diagnostic evaluation.

What Is Low Dose Naltrexone?

Naltrexone is an opioid receptor antagonist. FDA-approved oral naltrexone is used for specific alcohol- and opioid-related indications, commonly as a 50 mg tablet. Low Dose Naltrexone describes clinician-directed use at substantially lower doses for purposes outside the approved labeling.

There is no FDA-defined LDN product and no FDA-approved naltrexone indication for IBS, abdominal pain, SIBO, constipation, diarrhea, intestinal permeability, microbiome restoration, or weight loss. A patient-specific compounded low-dose formulation is also not FDA approved.

Proposed explanations for LDN include effects involving opioid signaling, pain processing, immune activity, and selected inflammatory pathways. Those hypotheses may justify clinical research. They do not prove that LDN repairs the intestinal barrier, changes the microbiome in a beneficial way, clears bacterial overgrowth, or normalizes motility.

For a broader overview, read what Low Dose Naltrexone is, including its uses, evidence, safety, and compounding.

What Did the 42-Person IBS Pilot Find?

The most commonly cited published IBS study was a 2006 open-label pilot involving 42 people. Participants received 0.5 mg of the investigational naltrexone formulation PTI-901 once daily for four weeks. Researchers tracked abdominal pain, stool urgency, consistency, frequency, pain-free days, and global symptom relief.

The study reported that:

• Global assessment improved in 76% of participants.

• Mean pain-free days per week increased from 0.5 at baseline to 1.25 during treatment.

• The change in pain-free days was statistically significant.

• No significant adverse reactions were reported during the small, short study.

Review the published IBS pilot.

These findings created a reason to conduct a larger controlled trial. They did not establish efficacy because the study had no placebo group, no blinding, only 42 participants, four weeks of treatment, and a per-protocol analysis.

IBS symptoms fluctuate, and placebo responses can be substantial. Participants may change diet, stress, sleep, activity, supplements, and other treatment during a study. A before-and-after improvement cannot show how much change LDN caused.

The 0.5 mg dose also matters. Online LDN discussions often focus on doses such as 1.5 to 4.5 mg. Evidence from 0.5 mg PTI-901 cannot automatically establish the effects of a different dose, formulation, schedule, or patient population.

The Larger Phase 3 Trial Missed Its Primary Endpoint

In December 2005, Pain Therapeutics announced results from a randomized, double-blind, multicenter Phase 3 trial of PTI-901. The trial compared daily PTI-901 with placebo in 609 women with documented IBS over three months.

The company's 2005 annual report filed with the U.S. Securities and Exchange Commission states that PTI-901 did not demonstrate a meaningful benefit during the third month, the study's primary endpoint. The company said the study was designed to detect durable benefit and discontinued further clinical development. Review the SEC filing.

Contemporary reporting indicated a statistically meaningful symptom-relief signal during the second month, but not during the third month. That means the prespecified durable endpoint was not met. Review the archived trial announcement.

The full trial does not appear to have been published in a peer-reviewed journal, limiting detailed assessment of participant characteristics, subtype results, attrition, adverse events, and secondary outcomes. That publication gap should not make the negative primary result disappear.

The correct conclusion is not that LDN can never help an individual. It is that the largest identified controlled IBS trial did not establish durable efficacy for the tested 0.5 mg product.

Why the Trial Timeline Can Be Confusing

The positive open-label pilot was published in 2006, while the Phase 3 failure was announced in December 2005. A publication date does not necessarily show the order in which the research program occurred. The pilot article and the larger program involved the same investigational 0.5 mg product, but online summaries frequently cite only the peer-reviewed pilot.

Evidence reviews should weigh study design and size, not merely whether a positive abstract is easy to find on PubMed.

LDN for IBS: Evidence at a Glance

Evidence question	What has been reported	What remains unproven
Small published pilot	A 42-person, four-week open-label study reported improved global assessment and more pain-free days	Benefit beyond placebo, durability, and the most responsive IBS subtype
Larger controlled trial	A randomized Phase 3 trial studied 609 women for three months	The primary endpoint was missed, and durable efficacy was not established
Abdominal pain	The pilot reported a before-and-after improvement signal	Reliable, sustained pain reduction in contemporary controlled trials
Constipation or diarrhea	Stool outcomes and different dosing approaches have been reported	Predictable normalization of bowel frequency, consistency, or transit
SIBO	A retrospective practice survey included an IBS-SIBO subgroup with mixed results	Eradication of bacterial overgrowth or replacement of diagnosis-directed care
“Gut healing”	Mechanistic theories involving signaling and inflammation exist	Repairing intestinal permeability, restoring the microbiome, or treating every cause of bloating
GLP-1 crossover	An investigational short-acting compound, ROSE-010, showed acute pain signals	Semaglutide or tirzepatide as established IBS treatments
LDN plus GLP-1	Both may be considered for separate goals after individualized review	A proven combination for IBS, motility, gut health, or enhanced weight loss

What Did the Gastrointestinal Practice Survey Report?

A 2010 retrospective survey provides additional real-world information, but it is difficult to interpret as efficacy evidence.

A single gastroenterology practice mailed surveys to 206 patients who had been prescribed naltrexone for IBS, chronic idiopathic constipation, or inflammatory bowel disease. Of 121 respondents, 74, or 61.2%, reported at least one side effect. Fifty-eight reported neurological complaints, and 32 reported gastrointestinal complaints. Twenty of the 74 respondents with side effects stopped treatment because of those effects.

The reported outcomes were mixed:

• Among 13 people described as having idiopathic IBS, two reported being markedly worse.

• Among 85 people described as having IBS with small intestinal bacterial overgrowth, 15 reported marked improvement, 32 reported moderate worsening, and one reported marked worsening.

• Among 12 people with chronic constipation, seven reported marked improvement, one moderate improvement, one mild improvement, and four no change.

Review the practice survey.

The subgroup counts and response categories reported in the abstract do not provide a clean, controlled efficacy estimate. The survey was retrospective, depended on who returned it, included different diagnoses and doses, lacked randomization and blinding, and relied on global self-report.

It is useful for one reason: it challenges the assumption that LDN is uniformly well tolerated or uniformly helpful in gastrointestinal disorders.

IBS Is Not the Same as Crohn's Disease or Ulcerative Colitis

Irritable bowel syndrome and inflammatory bowel disease, or IBD, are different conditions.

IBS is a disorder of gut-brain interaction. Crohn's disease and ulcerative colitis involve objective intestinal inflammation and can cause ulceration, bleeding, anemia, strictures, fistulas, and other complications. A person can have overlapping symptoms, but evidence cannot be transferred from one diagnosis to the other.

LDN has been studied in small Crohn's disease and IBD trials. Those studies do not establish that LDN treats IBS. Conversely, a pain signal in IBS does not prove control of intestinal inflammation in IBD.

Someone with blood in the stool, anemia, fever, weight loss, elevated inflammatory markers, or another alarm feature needs appropriate evaluation rather than an assumption that symptoms are “just IBS.”

Does LDN Treat SIBO?

That has not been established.

Small intestinal bacterial overgrowth, or SIBO, describes excess bacteria in the small intestine in an appropriate clinical context. Testing, interpretation, causes, recurrence, and treatment remain areas of clinical complexity. Symptoms such as bloating, abdominal discomfort, diarrhea, and constipation overlap with IBS and many other conditions.

The 2010 LDN practice survey included patients labeled with IBS-SIBO, but its mixed retrospective reports do not show bacterial eradication, normalization of breath testing, prevention of recurrence, or superiority to established approaches.

Describing LDN as a “prokinetic” for SIBO goes beyond the direct evidence. Even if a drug influences opioid signaling, that does not prove a clinically useful effect on the migrating motor complex or small-bowel clearance at the prescribed dose.

Does LDN Repair “Leaky Gut” or the Microbiome?

No adequate clinical evidence shows that LDN repairs intestinal permeability or restores a healthy microbiome in IBS.

Intestinal permeability, epithelial signaling, immune activation, and microbiome patterns are active research areas. They are not interchangeable, and no single test or mechanism explains every person's symptoms.

The phrase “leaky gut” is often used online as though it were one standardized diagnosis with one treatment. A mechanistic laboratory observation, biomarker difference, or result from inflammatory bowel disease cannot establish that compounded LDN repairs the intestinal lining in IBS.

Meaningful clinical research would need to define the population, measure validated IBS outcomes, include an appropriate comparator, prespecify permeability or microbiome endpoints, and show that any biological change corresponds to patient-important benefit.

What Established IBS Care Looks Like

IBS treatment is usually matched to the predominant symptom and subtype rather than built around one universal medication.

The ACG guideline supports several evidence-based strategies, including:

• A limited trial of a low-FODMAP diet for global IBS symptoms

• Chloride-channel activators and guanylate-cyclase activators for IBS-C

• Rifaximin for global IBS-D symptoms

• Gut-directed psychotherapy for global IBS symptoms

• Targeted diagnostic testing when celiac disease or inflammatory bowel disease needs to be excluded

These are not interchangeable recommendations for every patient. Diet changes are ideally guided by a qualified professional so that restrictive phases are time-limited and foods are systematically reintroduced. Medication selection depends on constipation, diarrhea, pain, bloating, comorbidities, prior response, and safety.

LDN should not be presented as a replacement for evaluation, dietary support, pelvic-floor assessment, gut-directed psychotherapy, or guideline-supported medication selected by the treating clinician.

A Practical Monitoring Plan for an Off-Label LDN Trial

If a prescriber determines that an LDN trial is reasonable, a structured plan is more informative than a vague goal of “better gut health.”

1. Define the target. Choose abdominal-pain days, urgency episodes, complete spontaneous bowel movements, stool consistency, bloating, or another measurable outcome.

2. Identify the IBS subtype. A person with IBS-C should not be monitored as though constipation and diarrhea were the same problem.

3. Record a baseline. Track symptoms, Bristol Stool Form Scale, meals, rescue medication, and important triggers before the first dose.

4. Review opioid exposure. Naltrexone can interfere with opioid analgesia and may precipitate withdrawal in opioid dependence.

5. Set the dosing and titration plan. The published IBS pilot used 0.5 mg, while off-label practice may use other doses. No FDA-approved IBS dose exists.

6. Avoid stacking changes. Simultaneously changing diet, probiotics, fiber, LDN, and a GLP-1 makes the result hard to interpret.

7. Choose a reassessment date. Decide when benefit, tolerability, and continuation will be reviewed.

8. Create a stop rule. Worsening pain, constipation, diarrhea, sleep, mood, or another effect should not be ignored because a treatment is labeled “low dose.”

Where Does the GLP-1 Research Fit?

A 2025 systematic review and meta-analysis reported that a GLP-1 receptor agonist reduced acute IBS pain compared with placebo. That headline needs an important qualifier: the trials evaluated ROSE-010, an investigational short-acting GLP-1 analogue administered by subcutaneous injection for IBS pain attacks.

They did not establish semaglutide or tirzepatide as IBS treatments.

In a randomized crossover study involving 166 people with IBS, single 100 microgram and 300 microgram ROSE-010 injections were compared with placebo. The primary pain-relief response occurred in 23% and 24% of participants after the active doses, compared with 12% after placebo. Nausea was more common with the higher dose. Review the randomized ROSE-010 trial.

The 2025 meta-analysis found a pooled acute pain-relief signal and also reported more nausea, vomiting, and headache. It called for further research on subtypes and long-term effects. Review the 2025 GLP-1 and IBS meta-analysis.

ROSE-010 is not a branded semaglutide or tirzepatide product, is not an established chronic IBS therapy, and should not be used as evidence that currently marketed GLP-1 weight-management medications improve IBS.

Semaglutide and Tirzepatide Can Overlap With IBS Symptoms

A person with IBS may also have obesity, type 2 diabetes, obstructive sleep apnea, cardiovascular risk, or another condition for which a specific GLP-1 or GIP/GLP-1 product may be appropriate. That is a separate treatment question.

Current Wegovy labeling lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, abdominal distension, flatulence, and gastroesophageal reflux among common adverse reactions. It warns about severe gastrointestinal reactions, says Wegovy is not recommended in severe gastroparesis, and notes delayed gastric emptying. Review current Wegovy prescribing information.

Current Zepbound labeling likewise lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, reflux, flatulence, and abdominal distension. It warns about severe gastrointestinal reactions, is not recommended in severe gastroparesis, and notes delayed gastric emptying and potential effects on oral-medication absorption. Review current Zepbound prescribing information.

These effects can imitate, worsen, or occasionally alter the symptoms a patient already attributes to IBS. A change after treatment might reflect:

1. The underlying IBS pattern

2. A GLP-1 adverse effect

3. Reduced food or fluid intake

4. A new dietary pattern

5. Constipation with overflow symptoms

6. Another gastrointestinal condition requiring evaluation

Weight loss or glucose improvement does not prove that IBS has improved. Conversely, early nausea or bowel-pattern change does not automatically mean the underlying IBS is permanently worse.

Can LDN and a GLP-1 Be Used Together?

There is no universal rule that automatically prevents every patient from being prescribed LDN with semaglutide or tirzepatide. There is also no clinical evidence establishing the combination as an IBS treatment, a gut-healing protocol, or a method for enhanced weight loss.

If both are considered, each should have a separate purpose:

• LDN: A clinician-directed off-label trial for a defined symptom target, with uncertain IBS efficacy.

• GLP-1 or GIP/GLP-1 therapy: Treatment for the exact product-specific metabolic indication selected by the prescriber.

Before starting, document abdominal pain, nausea, vomiting, reflux, early fullness, bloating, stool frequency, stool form, hydration, nutrition, and rescue medications. Starting one medication at a time, when clinically feasible, makes benefit and adverse effects easier to interpret.

The care team should also review oral medications whose absorption could matter, diabetes therapy, pregnancy plans, kidney function where relevant, gallbladder or pancreatic history, severe constipation, gastroparesis symptoms, and planned procedures.

Read the broader guide to LDN interactions involving opioids, GLP-1s, and other medications.

Opioids, Procedures, and Abdominal Pain Require Coordination

Naltrexone blocks opioid receptors. It can interfere with opioid pain relief and may precipitate withdrawal in someone who is physiologically dependent on an opioid. Patients should disclose prescription pain medicines, opioid-containing cough or diarrhea products, medications for opioid use disorder, and planned procedures.

GLP-1 medications can delay gastric emptying. Current product labels instruct patients to tell clinicians before procedures involving anesthesia or deep sedation because retained stomach contents may increase aspiration risk.

Patients should not create their own medication-free interval, stop LDN or a GLP-1 before a procedure, or attempt to overcome opioid blockade without clinician-directed guidance.

Severe abdominal pain should not automatically be dismissed as IBS or an expected medication effect. It may require assessment for obstruction, pancreatitis, gallbladder disease, severe constipation, appendicitis, or another urgent condition.

For additional information, read LDN side effects and opioid safety.

Where Does Retatrutide Fit?

Retatrutide is an investigational triple hormone-receptor agonist being studied for obesity and related conditions. It is not FDA approved, and there is no established evidence that it treats IBS, SIBO, intestinal permeability, or chronic abdominal pain.

The FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. Review the FDA's information about unapproved GLP-1 products.

Research involving ROSE-010 cannot be transferred to retatrutide. Both interact with GLP-1 pathways, but they are different investigational molecules with different pharmacology, dosing, development programs, and evidence.

Questions to Ask the Prescriber and Pharmacist

1. Has my symptom pattern been appropriately evaluated as IBS?

2. Which IBS subtype best describes my current bowel pattern?

3. Which exact symptom are we trying to improve with LDN?

4. How should the failed Phase 3 PTI-901 result affect expectations?

5. What dose and formulation are being proposed, and how do they compare with the studied 0.5 mg product?

6. How will we track pain, stool form, frequency, urgency, bloating, and rescue medication?

7. Do any of my medications or products contain an opioid or naltrexone?

8. If a GLP-1 is being considered, what separate metabolic condition is it intended to treat?

9. Should LDN and the GLP-1 be started at different times?

10. Which symptoms should prompt an urgent evaluation rather than routine follow-up?

The Bottom Line

The evidence does not support presenting LDN as a proven IBS treatment or universal gut-health solution.

A 42-person open-label pilot reported improved global symptoms and more pain-free days during four weeks of 0.5 mg PTI-901. A much larger randomized Phase 3 trial involving 609 women did not demonstrate meaningful benefit at the three-month primary endpoint, and development stopped. A later practice survey reported mixed outcomes and substantial side-effect reporting.

LDN has not been shown to repair “leaky gut,” restore the microbiome, clear SIBO, or reliably normalize constipation and diarrhea. An individualized off-label trial may still be discussed, but it should have a defined symptom target, a baseline, a reassessment date, and a stop plan.

The GLP-1 IBS pain research involved investigational ROSE-010, not semaglutide or tirzepatide. Marketed GLP-1 medications may be appropriate for a separate metabolic indication, but their gastrointestinal and motility effects can complicate IBS symptoms and treatment tracking.

Retatrutide remains investigational and cannot be compounded.

Talk With Scripx Pharmacy About a Patient-Specific Prescription

Scripx Pharmacy can help patients and prescribers review a patient-specific compounded LDN prescription, formulation questions, titration instructions, opioid precautions, and coordination with other medications. View LDN information, explore medically supervised weight-management services, or contact Scripx Pharmacy.

LDN use for IBS is off label. Compounded medications are not FDA approved. This article is educational and does not diagnose, treat, or replace individualized medical care.

FAQ Package

Is LDN FDA approved for IBS?

No. Naltrexone has FDA-approved uses at standard doses for specific alcohol- and opioid-related indications. LDN is an off-label dosing approach, and no naltrexone product is FDA approved to treat IBS, abdominal pain, constipation, diarrhea, SIBO, or “leaky gut.” A patient-specific compounded LDN formulation is not FDA approved.

Does LDN help IBS pain?

A 42-person open-label pilot reported increased pain-free days and improved global assessment during four weeks of 0.5 mg PTI-901. However, the study had no placebo group, and a later randomized Phase 3 trial in 609 women missed its three-month primary endpoint. Reliable and durable pain benefit remains unproven.

What happened in the large LDN IBS trial?

The manufacturer reported that the randomized, double-blind Phase 3 trial compared 0.5 mg PTI-901 with placebo in 609 women over three months. The drug did not demonstrate meaningful benefit during the third month, the primary endpoint, and further development was discontinued. Full peer-reviewed results do not appear to have been published.

Does LDN help constipation or diarrhea?

That has not been established. A retrospective practice survey reported mixed responses across gastrointestinal groups, and no contemporary randomized evidence establishes predictable normalization of stool frequency, consistency, or intestinal transit. IBS-C and IBS-D require different evaluation and treatment strategies.

Is LDN a prokinetic for SIBO?

LDN should not be described as a proven prokinetic or SIBO treatment. A retrospective survey included an IBS-SIBO subgroup, but it did not establish bacterial eradication, breath-test normalization, improved migrating motor complex function, or prevention of recurrence.

Does LDN heal leaky gut?

No adequate clinical evidence shows that LDN repairs intestinal permeability or restores the microbiome in people with IBS. Mechanistic theories and findings from other gastrointestinal diseases cannot establish patient-important benefit in IBS.

Do semaglutide or tirzepatide treat IBS?

Semaglutide and tirzepatide are not established IBS treatments. Research suggesting acute IBS pain relief evaluated the investigational compound ROSE-010, not marketed weight-management products. Semaglutide and tirzepatide can cause nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, and delayed gastric emptying.

Can LDN and a GLP-1 be taken together?

There is no universal prohibition against every combination, but no clinical evidence establishes LDN plus a GLP-1 as an IBS or gut-health protocol. Each medication should have a separate purpose. A prescriber and pharmacist should review gastrointestinal symptoms, hydration, nutrition, oral medications, opioid exposure, and the timing of starts.

Is ROSE-010 the same as Ozempic, Wegovy, or Zepbound?

No. ROSE-010 is an investigational short-acting GLP-1 analogue studied as an injection for acute IBS pain. It is not semaglutide or tirzepatide, and its research cannot establish that currently marketed GLP-1 products treat IBS.

Can retatrutide be compounded for IBS or weight loss?

No. Retatrutide is investigational and not FDA approved. The FDA states that retatrutide cannot be used in compounding under federal law. There is also no established evidence that it treats IBS or improves gut health.